Orange Book product · Brand (NDA)
NOXAFIL POWDERMIX KIT
POSACONAZOLE
At a glance
May 31, 2021
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 31, 2021
5 yr 2 mo ago
Today
Exclusivity ends · I-984
New indication exclusivity (3 years)
Jan 27, 2029
in 2 yr 8 mo
Pharmaceutical detail
Active ingredient
POSACONAZOLE
Strength
300MG
Dosage form
FOR SUSPENSION, DELAYED RELEASE
Route
ORAL
TE code
Not listed
Application
NDA 214770
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2014NOXAFILBrand (NDA)
NDA 205596 · MERCK SHARP DOHME
- 2013NOXAFILBrand (NDA)
NDA 205053 · MERCK SHARP DOHME
- 2006NOXAFILBrand (NDA)
NDA 022003 · SCHERING
- 2025POSACONAZOLEGeneric (ANDA)
ANDA 217720 · QILU PHARM HAINAN
- 2025POSACONAZOLEGeneric (ANDA)
ANDA 218434 · MSN
- 2024POSACONAZOLEGeneric (ANDA)
ANDA 219057 · ASPIRO
- 2024POSACONAZOLEGeneric (ANDA)
ANDA 217119 · AUROBINDO PHARMA
- 2023POSACONAZOLEGeneric (ANDA)
ANDA 214842 · EUGIA PHARMA
- 2023POSACONAZOLEGeneric (ANDA)
ANDA 209983 · FRESENIUS KABI USA
- 2023POSACONAZOLEGeneric (ANDA)
ANDA 217553 · GLAND
- 2023POSACONAZOLEGeneric (ANDA)
ANDA 211500 · MYLAN LABS LTD
- 2023POSACONAZOLEGeneric (ANDA)
ANDA 216488 · I 3 PHARMS
Marketing exclusivity (1)
- I-984New indication exclusivity (3 years)
Jan 27, 2029
in 2 yr 8 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

